Polyrizon Ltd. PLRZ 深 沪
已收盘 07-02 16:00:00 美东时间
13.80
+1.120
+8.83%
华盛通- 最 高13.83
- 今 开12.60
- 成交量 11.73万股
- 最 低 12.5227
- 昨 收 12.68
- 总市值 2583.15万
- 52周最高 18.20
- 市盈率 静 --
- 换手率 6.26%
- 52周最低 2.88
- 委 比 -87.94%
- 总股本 187.18万
- 历史最高 7200.00
- 量 比 8.75
- 振 幅 10.31%
- 历史最低 4.80
- 每 手 1
- 风险率 3.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Polyrizon Receives Central IRB Approval To Begin First Human Clinical Trial For NASARIX, Nasal Spray Designed To Block Airborne Allergens
Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, announced it has received central IRB approval to begin its first human clinical trial for NASARIX™, the Company’s innovative nasal spr...
06-29 20:45
Polyrizon receives U.S. patent publication notice for nasal drug delivery platform
Polyrizon (PLRZ) on Wednesday said it received notice of publication of a U.S. patent application covering its Trap & Target mucoadhesive polymer technology for nasal drug delivery. The patent applica...
06-17 20:53
Polyrizon Launches Human Study With Top European Medical Center To Validate NASARIX Allergy Blocker's Nasal Residence Time
New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker's protective barrier function Raanana, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" o...
06-15 20:10
Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
Polyrizon Ltd. has signed agreements with two additional U.S. clinical sites, bringing the total to three major contracted sites for its upcoming NASARIX™ (PL-14) clinical study. These sites are expected to contribute the highest rates of patient enrollment for evaluating the safety, tolerability, and efficacy of the NASARIX™ Allergy Blocker in patients with seasonal allergic rhinitis. The company believes this progress positions it strongly for ...
06-08 13:25
Polyrizon Ltd. Extends Exclusivity Period For Proposed 51% Acquisition Of Arrow Aviation Through June 30, 2026
As previously announced, on February 4, 2026, Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company") announced the signing of a non-binding Memorandum of Understanding (the "MOU"), with Arrow Aviation Ltd. ("Arrow Aviation"),
06-06 04:25
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
Polyrizon Ltd. has signed its first Clinical Trial Agreement with a U.S. allergy research site in Texas to initiate a multi-center study evaluating the safety, tolerability, and efficacy of its NASARIX™ allergy blocker for seasonal allergic rhinitis. The trial, titled "Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray," aims to validate the investigational nasal spray designed to create a prote...
05-13 13:25
Pulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable Protection
In light of the growing challenges posed by emerging respiratory threats, including recent Hantavirus, Polyrizon is advancing a biophysical barrier technology that may offer immediate, non-s...
05-11 19:25
Polyrizon Expands U.S. Patent Claims for Intranasal Drug Delivery Platform
Polyrizon Ltd. ( ($PLRZ) ) has shared an update. On May 4, 2026, Polyrizon Ltd....
05-04 21:17
Polyrizon expands U.S. patent claims for intranasal drug delivery platform
Polyrizon expands U.S. patent claims for intranasal drug delivery platform Polyrizon submitted amended claims in a U.S. patent application to broaden protection for its intranasal drug-delivery hydrogel platform beyond core mucoadhesive composition to cover drug-delivery systems and methods of use.
05-04 20:54
